Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy

Hyperprogressive disease (HPD) is a paradoxical phenomenon involving the acceleration of tumor progression after treatment with immune checkpoint inhibitors (ICIs). A 66-year-old male smoker with advanced lung adenocarcinoma started pembrolizumab for progressive disease following first-line chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Okeya, Komugi, Kawagishi, Yukio, Muranaka, Emiri, Izumida, Toshihide, Tsuji, Hiroshi, Takeda, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911749/
https://www.ncbi.nlm.nih.gov/pubmed/31327828
http://dx.doi.org/10.2169/internalmedicine.2892-19
_version_ 1783479316503330816
author Okeya, Komugi
Kawagishi, Yukio
Muranaka, Emiri
Izumida, Toshihide
Tsuji, Hiroshi
Takeda, Shinichi
author_facet Okeya, Komugi
Kawagishi, Yukio
Muranaka, Emiri
Izumida, Toshihide
Tsuji, Hiroshi
Takeda, Shinichi
author_sort Okeya, Komugi
collection PubMed
description Hyperprogressive disease (HPD) is a paradoxical phenomenon involving the acceleration of tumor progression after treatment with immune checkpoint inhibitors (ICIs). A 66-year-old male smoker with advanced lung adenocarcinoma started pembrolizumab for progressive disease following first-line chemotherapy. He developed HPD after two cycles, and a re-biopsy revealed transformation to small-cell carcinoma. He subsequently underwent two lines of chemotherapy for small-cell carcinoma until progression and ultimately died. Transformation to small-cell carcinoma may be a cause of HPD during ICI therapy. The possibility of pathological transformation should be considered in cases of HPD with resistance to ICI therapy.
format Online
Article
Text
id pubmed-6911749
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-69117492019-12-16 Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy Okeya, Komugi Kawagishi, Yukio Muranaka, Emiri Izumida, Toshihide Tsuji, Hiroshi Takeda, Shinichi Intern Med Case Report Hyperprogressive disease (HPD) is a paradoxical phenomenon involving the acceleration of tumor progression after treatment with immune checkpoint inhibitors (ICIs). A 66-year-old male smoker with advanced lung adenocarcinoma started pembrolizumab for progressive disease following first-line chemotherapy. He developed HPD after two cycles, and a re-biopsy revealed transformation to small-cell carcinoma. He subsequently underwent two lines of chemotherapy for small-cell carcinoma until progression and ultimately died. Transformation to small-cell carcinoma may be a cause of HPD during ICI therapy. The possibility of pathological transformation should be considered in cases of HPD with resistance to ICI therapy. The Japanese Society of Internal Medicine 2019-07-22 2019-11-15 /pmc/articles/PMC6911749/ /pubmed/31327828 http://dx.doi.org/10.2169/internalmedicine.2892-19 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Okeya, Komugi
Kawagishi, Yukio
Muranaka, Emiri
Izumida, Toshihide
Tsuji, Hiroshi
Takeda, Shinichi
Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
title Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
title_full Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
title_fullStr Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
title_full_unstemmed Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
title_short Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
title_sort hyperprogressive disease in lung cancer with transformation of adenocarcinoma to small-cell carcinoma during pembrolizumab therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911749/
https://www.ncbi.nlm.nih.gov/pubmed/31327828
http://dx.doi.org/10.2169/internalmedicine.2892-19
work_keys_str_mv AT okeyakomugi hyperprogressivediseaseinlungcancerwithtransformationofadenocarcinomatosmallcellcarcinomaduringpembrolizumabtherapy
AT kawagishiyukio hyperprogressivediseaseinlungcancerwithtransformationofadenocarcinomatosmallcellcarcinomaduringpembrolizumabtherapy
AT muranakaemiri hyperprogressivediseaseinlungcancerwithtransformationofadenocarcinomatosmallcellcarcinomaduringpembrolizumabtherapy
AT izumidatoshihide hyperprogressivediseaseinlungcancerwithtransformationofadenocarcinomatosmallcellcarcinomaduringpembrolizumabtherapy
AT tsujihiroshi hyperprogressivediseaseinlungcancerwithtransformationofadenocarcinomatosmallcellcarcinomaduringpembrolizumabtherapy
AT takedashinichi hyperprogressivediseaseinlungcancerwithtransformationofadenocarcinomatosmallcellcarcinomaduringpembrolizumabtherapy

Ejemplares similares